Personalize every critical treatment decision

for improved patient outcomes.​

Matching patients with advanced-stage cancer to the right treatment at the right time can be achieved through comprehensive molecular profiling.1​

*This chart utilizes percent target alterations found by liquid and tissue CGP testing from the European Journal of Cancer Cui et al study. Turnaround time is defined as 7 days for liquid biopsy and 14 days for tissue genotyping. This information is based on Guardant Health data on file.

†Data shown for only the Tier 1 variants assessed in the Cui et al study. A Tier 1 variant is defined as an actionable biomarker with the most substantial clinical significance, including those related to
FDA-approved treatments, proposed by professional guidelines, and/or with a strong consensus of predictive value.5

‡Data shown for actionable biomarkers assessed in the study.

§Liquid and tissue testing may be initiated at the same time, but sample processing does not occur concurrently.

||Patients who have a negative Guardant360 CDx test result for an indicated companion diagnostic biomarker should be reflexed to tissue biopsy testing using an FDA-approved tumor tissue test, if feasible. Guardant360 TissueNext has not been cleared or approved by the FDA. For the complete intended use statement including companion diagnostic indications for Guardant360 CDx, please see Guardant360 CDx Technical Information.

1L, first-line; CRC, colorectal cancer; ctDNA, circulating tumor DNA; NCCN, National Comprehensive Cancer Network®; NSCLC, non-small cell lung cancer.

References: 1. Matsubara J, Mukai K, Kondo T, et al. First-line genomic profiling in previously untreated advanced solid tumors for identification of targeted therapy opportunities. JAMA Netw Open. 2023;6(7):e2323336. doi:10.1001/jamanetworkopen.2023.23336 2. Aggarwal C, Marmarelis ME, Hwang WT, et al. Association between availability of molecular genotyping results and overall survival in patients with advanced nonsquamous non–small-cell lung cancer. JCO Precis Oncol. 2023;7:e2300191. doi:10.1200/PO.23.00191 3. Benavides M, Alcaide-Garcia J, Torres E, et al. Clinical utility of comprehensive circulating tumor DNA genotyping compared with standard of care tissue testing in patients with newly diagnosed metastatic colorectal cancer. ESMO Open. 2022;7(3):100481. doi:10.1016/j.esmoop.2022.100481 4. Guo H, Zhang J, Qin C, et al. Biomarker-targeted therapies in non-small cell lung cancer: current status and perspectives. Cells. 2022;11(20):3200. doi:10.3390/cells11203200 5. Cui W, Milner-Watts C, O’Sullivan H, et al. Up-front cell-free DNA next generation sequencing improves target identification in UK first line advanced non-small cell lung cancer (NSCLC) patients. Eur J Cancer. 2022;171:44-54. doi:10.1016/j.ejca.2022.05.012 6. Riely GJ, Wood DE, Ettinger DS, et al. NCCN Guidelines® Insights: Non-Small Cell Lung Cancer, Version 5.2024, NCCN clinical practice guidelines in oncology. Accessed October 8, 2024. https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf 7. Guardant360 TissueNextTM Assay Specifications. Guardant Health, Inc. Redwood City, CA. 8. Martins I, Ribeiro IP, Jorge J, et al. Liquid biopsies: applications for cancer diagnosis and monitoring. Genes (Basel). 2021;12(3):349. doi:10.3390/genes12030349 9. Papadimitrakopoulou VA, Wu YL, Han JY, et al. Analysis of resistance mechanisms to osimertinib in patients with EGFR T790M advanced NSCLC from the AURA3 study. Ann Oncol. 2018;29(suppl 8). doi:10.1093/annonc/mdy424 
10. Aggarwal C, Thompson JC, Black TA, et al. Clinical implications of plasma-based genotyping with the delivery of personalized therapy in metastatic non–small cell lung cancer. JAMA Oncol. 2019;5(2):173-180. doi:10.1001/jamaoncol.2018.4305 11. Parikh AR, Leshchiner I, Elagina L, et al. Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers. Nat Med. 2019;25(9):1415-1421. doi:10.1038/s41591-019-0561-9 12. Mayrhofer M, De Laere B, Whitington T, et al. Cell-free DNA profiling of metastatic prostate cancer reveals microsatellite instability, structural rearrangements, and clonal hematopoiesis. Genome Med. 2018;10(1):85. doi:10.1186/s13073-018-0595-5 13. Bardia A, Kaklamani V, Wilks S, et al. Phase I study of elacestrant (RAD1901), a novel selective estrogen receptor degrader, in ER-positive, HER2-negative advanced breast cancer. J Clin Oncol. 2021;39(12):1360-1370. doi:10.1200/JCO.20.02272 14. Zundelevich A, Dadiani M, Kahana-Edwin S, et al. ESR1 mutations are frequent in newly diagnosed metastatic and loco-regional recurrence of endocrine-treated breast cancer and carry worse prognosis. Breast Cancer Res. 2020;22(1):16. doi:10.1186/s13058-020-1246-5